drugset / Trial / NCT06315634

Intrathecal Dexmedetomidine vs Midazolame

NCT06315634

Phase 4 Completed 75 enrolled National Cancer Institute, Egypt
RandomizedParallel-groupTriple-blindTreatment

Summary

Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries

Timeline

Start
2021-03-15
Primary completion
2022-03-10
Completion
2022-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 5 ug Intrathecal
Subject Midazolam Small molecule 2 mg Intrathecal
Background Bupivacaine Other / unclassified 12.5 mg Intrathecal

Indications

No indication recorded.